View Post

Endoxifen Shows Promise in Treating Breast Cancer in Australian Trial, Development in the US to Accelerate

In Clinical Trials by Barbara Jacoby

By: Ryan McDonald From: curetoday.com Results of a trial assessing endoxifen in patients with breast cancer in Australia were positive enough for the manufacturer to stop the trial before it was scheduled to be completed. The drug’s manufacturer will now accelerate its development in the U.S. Treatment with oral endoxifen during the “window of opportunity” between breast cancer diagnosis and …

View Post

Endoxifen Uses Window-of-Opportunity to Reduce Tumor Activity in Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Nichole Tucker From: targetedonc.com Administering endoxifen in the window of opportunity between diagnosis and treatment may be effective for reducing tumor activity in patients with breast cancer. In the opening between breast cancer diagnosis and surgery, endoxifen may be effective for reducing tumor cell proliferation, leading to Ki-67 change, according to interim analysis results from a phase II clinical …

View Post

Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

In Clinical Trials by Barbara Jacoby

Source: Atossa Genetics Inc. From: globenewswire.com Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the FDA has issued a “Safe to Proceed” letter under their “expanded access” program permitting the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, …